Australia's largest stock trading and investment forum Australia's #1 stock forum

AGY

2.63%

3.9¢ argosy minerals limited

General Discussion AGY, page-22283

First 22283 Last

Share
Profile

Follow
Howard Ino

12,006 Posts.

669

09/04/24

13:24

Post #: 73258055
Share

Originally posted by GCar ↑

"...maybe this was just an initial oversight by JZ and AGY are now aiming to produce a feasibility study so that ..."

No, AGY has specifically stated - for several years (DYOR the announcements are there for everyone to read) - that updating the resource via further exploration work will lead to a feasibility study for a larger capacity operation.

The resource upgrade landed in Jan this year.
Discussion of drilling delays etc are in the archives.

We just received estimates for increased production scenarios based on modelling of that upgraded resource. Great.

The feasibility study is built upon these things, and upcoming work including that around financial modelling of potential production scenarios.

Producing a feasibility study has NOT at all been a recent decision.
The priority has always been de-risking the processing technology; producing a feasibility study has not been on the critical path, afaict, like it is for most juniors who take a more conventional approach and would stall all/most activity without one.

The company is working through the steps in the order and with the priority that they deem most suitable. Simple.

Your suggestion that producing a feasibility study is "maybe" a recent decision due to prior oversight is not accurate at all.

Carry on.

Expand

https://carboncredits.com/key-challenges-and-opportunities-in-global-lithium-metal-market/

AGY Price at posting: 13.5¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 1,483 more messages in this thread...

First 22283 Last

Add AGY (ASX) to my watchlist

(20min delay)
Last 3.9¢		Change 0.001(2.63%)		Mkt cap ! $56.78M

Open	High	Low	Value	Volume
4.0¢	4.1¢	3.9¢	$303.9K	7.541M

Buyers (Bids)

No.	Vol.	Price($)
3	304999	3.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	25000	1

View Market Depth

No.	Vol.	Price($)
3	304999	0.039
7	563206	0.038
5	648648	0.037
22	2110708	0.036
25	2513178	0.035

Price($)	Vol.	No.
0.040	25000	1
0.041	406425	2
0.042	751292	7
0.043	1956941	3
0.044	1035285	9

Last trade - 16.10pm 07/10/2024 (20 minute delay)

AGY (ASX) Chart

General Discussion AGY, page-22283

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

General Discussion AGY, page-22283

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News